Drug news
Kynamro (Genzyme/Sanofi)is filed at FDA for Homozygous Familial Hypercholesterolaemia
Kynamro(mipomersen) from Genzyme/Sanofi and Isis Pharma has been filed at the FDA as a New Drug Application for the rare genetic condition of Homozygous Familial Hypercholesterolaemia. The first-in-class apo-B synthesis inhibitor was filed in Europe in July last year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins